SCHEMBL425168

SCHEMBL425168

Cc1ccc2cnn(C)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.57
NOTUM Q6P988 1/20 0.45
ERCC1 P07992 1/20 0.44
ERCC4 Q92889 1/20 0.44
PDE1C Q14123 1/20 0.43
CYP1A2 P05177 3/20 0.42
CYP2A6 P11509 2/20 0.42
CDK8 P49336 2/20 0.40
MAPT P10636 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CYP11B2 P19099 1/20 0.40
MPO P05164 1/20 0.40
GRM4 Q14833 1/20 0.39
ESRRG P62508 1/20 0.39
HTR2A P28223 2/20 0.39
HTR2C P28335 2/20 0.39
HTR2B P41595 1/20 0.39
QPCT Q16769 1/20 0.39
TLR8 Q9NR97 1/20 0.38
VNN1 O95497 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29901474 1.00 KMO (0.57) KMONOTUMERCC1ERCC4PDE1C
SCHEMBL29769166 0.83 TRPA1 (0.46) KMOPDE1CCYP1A2CYP2A6MAPT
SCHEMBL424964 0.83 TRPA1 (0.46) KMOPDE1CCYP1A2CYP2A6MAPT
SCHEMBL18751498 0.81 NR3C1 (0.50) KMOERCC1ERCC4CDK8CCNC
SCHEMBL8297789 0.79 KMO (0.53) KMOCYP1A2CYP2A6MAPTRXFP1
SCHEMBL13607530 0.79 KMO (0.60) KMONOTUMCYP1A2CYP2A6HTR2A
SCHEMBL19703376 0.78 KMO (0.64) KMOCYP1A2HTR2AHTR2CHTR2B
SCHEMBL13607684 0.78 KMO (0.68) KMOHTR2AHTR2CHTR2B
SCHEMBL15344155 0.78 IRAK4 (0.48) KMOERCC1ERCC4CYP2A6CDK8
SCHEMBL2144057 0.78 NOTUM (0.44) KMONOTUMERCC1ERCC4PDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE AMGEN INC. 2024-02-22 US disclosed
WO-2024006403-A2 SELECTIVE HISTONE DEACETYLASE 8 (HDAC8) DEGRADERS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-04 WO disclosed
EP-3628044-B1 PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS UNIV MICHIGAN REGENTS (US) 2023-11-22 EP disclosed
US-20230365556-A1 N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. (US) 2023-11-16 US disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS THE UNIVERSITY OF HONG KONG (CN) 2023-11-09 US disclosed
EP-4265608-A1 BENZOHETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2023-10-25 EP disclosed
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
US-20080090856-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-04-17 US disclosed
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 US disclosed
WO-2007067537-A1 PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2007-06-14 WO disclosed
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds OSI PHARMACEUTICALS, INC. 2007-06-07 US disclosed
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds OSI PHARMACEUTICALS, INC. 2007-06-07 US disclosed
WO-2007042299-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
US-20070078121-A1 Enzyme modulators and treatments DECIPHERA PHARMACEUTICALS, LLC 2007-04-05 US disclosed
US-20070015794-A1 Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-18 US disclosed
WO-1992022536-A1 VINYLIMIDAZOLES, VINYLTRIAZOLES AND VINYLTETRAZOLES WITH A BICYCLIC SUBSTITUENT GROUP SCHERING AKTIENGESELLSCHAFT, BERLIN UND BERGKAMEN (DE) 1992-12-23 WO disclosed
EP-0518457-A1 Bicyclic substituted vinylimidazoles, -triazoles and -tetrazoles SCHERING AKTIENGESELLSCHAFT (DE) 1992-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL KMO 1082/4885NOTUM 3025/4885ERCC1 3505/4885
US-20070015794-A1 Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents FLT4, KDR, FLT1 KMO 178/4885NOTUM 3697/4885ERCC1 2848/4885
US-20080090856-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES MYLK3, MYLK, CDK3 KMO 2076/4885NOTUM 2494/4885ERCC1 3253/4885
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A KMO 31/4885NOTUM 3792/4885ERCC1 3565/4885
US-20240059703-A1 HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE KRAS, HRAS, APC KMO 4650/4885NOTUM 4200/4885ERCC1 229/4885
US-20070129364-A1 Pyrrolopyridine kinase inhibiting compounds BMX, ERBB2, FRK KMO 1842/4885NOTUM 3813/4885ERCC1 2665/4885
US-20230365556-A1 N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE ITGA1, ITGB1, ITGAL KMO 3577/4885NOTUM 3488/4885ERCC1 4555/4885
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors AXL, TYRO3, FLT3 KMO 2571/4885NOTUM 2875/4885ERCC1 4491/4885
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS YEATS2, YEATS4, KNTC1 KMO 1972/4885NOTUM 2798/4885ERCC1 858/4885
US-20070078121-A1 Enzyme modulators and treatments ABL1, ABL2, LCK KMO 2024/4885NOTUM 2504/4885ERCC1 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.